← Issue №18/
week of Nov 1, 2026/
the whole section, in full
Hepatology, in full.
All 32 Hepatology papers in this issue,
as full cards, ranked by clinical utility. The issue page carries the strongest few;
this is the section, whole.
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Hepatologymeta analysis · n=2,456 · Oct 27, 2026 · Clin Gastro Hep · IF 16.2
New evidenceautoimmune hepatitisacute liver failuresystematic reviewmeta-analysis
Clinical takeawayConsider acute presentations in nearly 40% of AIH patients, and prioritize timely therapy for acute severe AIH and acute/severe exacerbations, as these have favorable outcomes (79% TFS) compared to AIH-associated acute liver failure (19% TFS). Monitor AIH-associated acute liver failure closely due to poor transplant-free survival. Note that therapy should be tailored to disease severity and patient-specific factors, and adverse events should be monitored.
What it found39% of AIH patients present acutely, with 90-day transplant-free survival varying from 79% for acute severe AIH to 19% for AIH-associated acute liver failure.
ContextConfirms that acute presentations are common in AIH and highlights the heterogeneity in outcomes, refining understanding of clinical trajectories across subtypes. Applicable to adult patients with varying severity of AIH.
Emergingsuggested applicable standard· European Association for the Study of the Liver (EASL), 'EASL Clinical Practice Guidelines on the management of autoimmune hepatitis,' Journal of Hepatology, 2025 (vol. 83, no. 2, pp. 453-501)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
In adults with AIH, first-line induction is predniso(lo)ne of AT LEAST 0.5 mg/kg/day, potentially up to 1 mg/kg/day in more severe and advanced disease, in combination with EITHER azathioprine OR mycophenolate mofetil (LoE 2, strong recommendation; 82% agreement). Azathioprine is added only when bilirubin is <6 mg/dL and ideally 2 weeks after corticosteroid start (to avoid confusing non-response with azathioprine toxicity), at an initial dose of 50 mg/day titrated to a final dose of 1-2 mg/kg/day according to toxicity and response; azathioprine must never be used alone as induction; before starting azathioprine, thiopurine methyltransferase (TPMT) activity should ideally be tested to exclude COMPLETE (absent) TPMT activity, in which azathioprine is CONTRAINDICATED because of the risk of severe, potentially life-threatening myelosuppression, whereas in PARTIAL (intermediate/heterozygous) TPMT deficiency it may be used only with caution and dose reduction; azathioprine should likewise be given cautiously in pregnancy, cytopenias or malignancy, and should be AVOIDED in acute severe AIH and decompensated cirrhosis. Mycophenolate mofetil is dosed 1.5-2 g/day (0.75-1.0 g twice daily) and is positioned by EASL as an alternative first-line option to azathioprine; the CAMARO RCT found MMF superior to azathioprine in treatment-naive patients (CBR at 6 months 72.2% vs 32.3%, p=0.004) with fewer severe adverse events (0% vs 12.9%) and less withdrawal (5.1% vs 25.8%). MMF is teratogenic and counselling of both female and male patients is recommended (LoE 2, strong); it must be withdrawn at least 3 months before conception, and first presentations during pregnancy are treated with standard regimens EXCLUDING MMF. Induction therapy and corticosteroid tapering should be individualised according to CBR status (LoE 4, strong). Budesonide is NOT recommended as part of first-line treatment for AIH and is CONTRAINDICATED in patients with cirrhosis (LoE 2, strong; 82%), but it retains a defined second-line role: switching to budesonide may be suggested because of corticosteroid side effects in patients WITHOUT cirrhosis who are predniso(lo)ne-dependent (LoE 3, WEAK recommendation; 91%). Maintenance after CBR should consist of azathioprine or MMF as monotherapy OR in combination with low-dose corticosteroids (predniso(lo)ne ≤5 mg/day), with the dose adapted to sustain stable CBR (LoE 2, strong); low-dose predniso(lo)ne monotherapy can be suggested ONLY in patients with mild disease who achieved CBR and are intolerant to both azathioprine and MMF (LoE 3, weak). Most patients require long-term, often lifelong immunosuppression, and a trial of stopping is appropriate only in carefully selected patients whose low-dose monotherapy has maintained stable CBR for at least 2 years. For ACUTE SEVERE AIH the guideline stratifies by liver failure: in acute severe AIH WITHOUT ALF or ACLF, an early treatment trial with predniso(lo)ne 0.5-1 mg/kg/day (or intravenous methylprednisolone at equivalent dose) is recommended, and failure to improve after 3-7 days of treatment initiation should trigger REFERRAL TO A LIVER TRANSPLANT CENTRE (LoE 3, strong; 91%); in acute severe AIH WITH ALF or ACLF, direct evaluation (discussion with a transplant centre) for liver transplantation is recommended, because data on the role of corticosteroids in these patients is very limited and outcomes are poor (LoE 3, strong; 97%), and if corticosteroids are given, strict surveillance for infection and close monitoring of efficacy is recommended.
Taneja S … Duseja A · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyguideline · Nov 1, 2026 · Gastroenterology · IF 25.1
Clinical takeawaySix recommendations: PBC-specific antinuclear antibodies in AMA-negative suspected PBC, UDCA first line, liver stiffness for prognosis, PPAR agonists for inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA after transplant to reduce recurrence. Certainty of evidence was moderate to very low.
What it foundThe guideline provides 6 recommendations, including UDCA as first-line therapy, liver stiffness measurement for prognostication, and linerixibat for moderate to severe pruritus, compared to older therapies like rifampin and naltrexone.
ContextThis guideline refines current practice by providing evidence-based recommendations for diagnosis, treatment escalation, symptom management, and post-transplantation care in adults with PBC.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice GuidanceShowHide
Decision at stakethe use of UDCA as first-line therapy for PBC
Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces.…If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead.…After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.
Clinical takeawayConsider using SomaSignal as a non-invasive biomarker for detecting at-risk MASH, advanced fibrosis, and cirrhosis in MASLD patients, potentially reducing the need for liver biopsy, but further validation in diverse populations is needed.
What it foundSomaSignal achieved AUC 0.83 for at-risk MASH, AUC 0.92 for advanced fibrosis, and AUC 0.92 for cirrhosis, exceeding the minimum acceptable criterion (AUC >0.80) for biopsy replacement, compared to other non-invasive biomarkers.
ContextThis study provides robust evidence supporting the use of non-invasive biomarkers in MASLD, refining the diagnostic approach and potentially replacing biopsy in certain cases, though limitations and adverse events were not reported.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
Decision at stakethe use of non-invasive tests to identify patients with at-risk MASH and advanced fibrosis
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range.…Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
New evidencehepatocellular carcinomaMASLDbiomarkerepidemiology
Clinical takeawayIn steatotic liver disease, an aMAP above 64 marked a very-high-risk group (15-year HCC incidence 3.1% to 5.4%) that the authors judge reaches the surveillance threshold; the refined cutoff was derived and validated within the UK Biobank.
What it foundThe aMAP score stratified HCC risk in SLD patients, with a 15-year cumulative incidence of 1.43% in the high-risk group vs. 0.06% in the low-risk group (HR 28.51, 95% CI 19.58-41.52), and a refined cutoff (aMAP > 64) identified a very-high-risk subgroup.
ContextaMAP, developed mainly in viral hepatitis, discriminated HCC risk in steatotic liver disease (C-index 0.80 in UK Biobank, 0.79 in a Chinese cohort) and was compared with PAGE-B, mPAGE-B, CAMD and MASLD-HCC.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.
Xu W … Chronic Hepatitis B Study Consortium · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyprospective cohort · n=162,456 · Oct 27, 2026 · Clin Gastro Hep · IF 16.2
Clinical takeawayIn routine Stockholm care data, high-risk FNI with a cardiometabolic risk factor carried 4.6-fold the MALO rate of low FNI; whether acting on FNI changes outcomes was not tested.
What it foundHigh-risk FNI patients (FNI≥0.33 and ≥1 cardiometabolic risk factor) had a 4.6-fold higher risk of major adverse liver outcomes (MALO) compared to low-risk FNI patients (FNI<0.1).
ContextThis study highlights the utility of FNI in identifying undiagnosed MASH patients at high risk of adverse outcomes, reinforcing the need for earlier diagnosis and intervention in this population.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Grip ET … Hagström H · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyrct · n=50 · Nov 1, 2026 · Liver International · IF 6.7
Clinical takeawayConsider recommending a 16-week moderate-intensity aerobic exercise program (e.g., brisk walking) to improve functional capacity and portal vein hemodynamics in patients with compensated cirrhosis, while acknowledging the lack of between-group significance in autonomic and hepatic parameters.
What it foundAerobic exercise improved 6-minute walk test distance by 32 meters (IQR: 12.00-51.60 m, p < 0.01) compared to nutritional consultation alone and increased portal vein volume flow by 350.66 mL/min (p = 0.003) in compensated cirrhosis, though positive signals in autonomic and hepatic parameters were not between-group significant.
ContextThis RCT provides evidence that aerobic exercise is safe and beneficial in compensated cirrhosis, refining prior observational data on exercise in liver disease.
Measured against the standard of care· ACG 2026 (Tapper EB et al., ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis, Am J Gastroenterol, online 2026-10-05)ShowHide
…Carvedilol is also suggested in compensated cirrhosis with clinically significant portal hypertension to prevent a first episode of ascites; CSPH can be estimated noninvasively from transient elastography plus platelet count.…Structured aerobic and resistance exercise for ambulatory patients.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
ACG 2026 (Tapper et al., Am J Gastroenterol, online 2026-10-05) gives 18 GRADE recommendations and 6 key concepts on preventive care in cirrhosis; most of the evidence is low certainty. Varices: carvedilol (12.5 mg daily, with no titration to a heart-rate target) or endoscopic variceal ligation as primary prophylaxis for high-risk esophageal varices. This is strong, and it is the only moderate-certainty recommendation. Carvedilol is also suggested in compensated cirrhosis with clinically significant portal hypertension to prevent a first episode of ascites; CSPH can be estimated noninvasively from transient elastography plus platelet count. HCC: ultrasound plus AFP every 6 months for patients who are candidates for HCC treatment (strong). Aspirin is not recommended for HCC prevention, and statins should not be started only for chemoprevention without a conventional cardiovascular indication. Vaccination: test hepatitis A immunity and vaccinate if not immune; annual influenza; a SARS-CoV-2 series; RSV (bivalent vaccine) at age 50 or older; all strong. Test hepatitis B immunity and vaccinate (conditional), and revaccinate non-responders, considering the TLR9-adjuvanted vaccine. Hepatic encephalopathy: lactulose over no treatment for minimal HE; no rifaximin for primary prevention in minimal HE; add rifaximin if overt HE develops on lactulose. Upper GI bleeding, variceal or not: a 2-3 day course of prophylactic antibiotics. Albumin 6-8 g per liter removed for paracentesis over 5 L. Nutrition: dietitian-guided, protein 1.2-1.5 g/kg ideal body weight per day and 30-35 kcal/kg per day, lower in obesity. Structured aerobic and resistance exercise for ambulatory patients. Bisphosphonates for osteoporosis; varices alone do not rule out oral bisphosphonates. Screen for alcohol use disorder at every visit, treat with naltrexone or acamprosate, and offer behavioral therapy after discharge to hospitalized patients with AUD. Smoking-cessation counseling (strong). Clinic follow-up within 14 days of discharge. Consider age-appropriate cancer screening for transplant candidates and for non-frail compensated patients without life-limiting comorbidity.
Kittiprachakul S … Chaiteerakij R · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyretrospective · n=1,234 · Nov 1, 2026 · Liver International · IF 6.7
Clinical takeawayConsider HDV screening in HBsAg-positive individuals, as HIV status no longer identifies a higher-risk subgroup.
What it foundAnti-HDV prevalence among HBsAg-positive PWH declined from 19.1% to 12.5%, converging with HIV-negative individuals (12.7%), and HIV status was no longer independently associated with HDV infection.
ContextChallenges prior practice of targeting HDV screening primarily in PWH, supporting broader screening in HBsAg-positive individuals.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Puoti M … PITER, MASTER and ICONA Study Groups · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologymeta analysis · n=5,045 · Nov 1, 2026 · Liver International · IF 6.7
New evidencealcohol-associated liver diseasemeta-analysissystematic reviewbiomarker
Clinical takeawayNot a basis for routine use: the effect disappeared when only low-risk-of-bias studies were analysed, and the authors call for adequately powered trials.
What it foundGranulocyte colony stimulating factor (GCSF) reduced 90-day mortality risk by 51% (RR 0.49, 95% CI 0.28-0.84) compared to placebo in acute alcohol-associated hepatitis, though subgroup analysis of low-risk-of-bias studies showed no significant effect.
ContextChallenges current practice: no treatment has shown consistent survival benefit in AH, and GCSF emerges as a promising candidate, though further high-quality trials are needed.
Emergingsuggested applicable standard· American College of Gastroenterology (ACG), "ACG Clinical Guideline: Alcohol-Associated Liver Disease" (Jophlin, Singal, Bataller, et al.), Am J Gastroenterol 2024;119(1):30-54ShowHide
…For alcohol-associated hepatitis (AH), severity is stratified by MELD: MELD >20 defines severe AH, which carries high short-term mortality and should preferably be managed in hospital; MELD ≤20 defines moderate AH.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Treatment of AUD with sustained abstinence is the most effective strategy to prevent progression and improve long-term outcomes at any stage of ALD; ACG recommends brief screening with a tool such as AUDIT-C (strong, high), brief motivational interventions (strong, low), and integrated multidisciplinary care combining behavioral therapy and/or pharmacotherapy (strong, low). AUD pharmacotherapy recommendations are scoped specifically to COMPENSATED ALD and are not co-equal: baclofen is recommended as an option (strong recommendation, moderate evidence); acamprosate or naltrexone are only suggested as options (conditional, very low); gabapentin or topiramate are suggested as options (conditional, very low); disulfiram is suggested AGAINST along any spectrum of ALD (conditional, very low). For severe alcohol withdrawal, benzodiazepines are the treatment of choice but with explicitly cautious use and careful monitoring given their potential to precipitate or exacerbate hepatic encephalopathy (strong, moderate); AWS is managed per CIWA-Ar protocol, differentiating it from HE while acknowledging the two can coexist. For alcohol-associated hepatitis (AH), severity is stratified by MELD: MELD >20 defines severe AH, which carries high short-term mortality and should preferably be managed in hospital; MELD ≤20 defines moderate AH. In severe AH (MELD >20) ACG recommends corticosteroid therapy ONLY if there are no contraindications (strong, moderate); active infection (including untreated HBV infection), uncontrolled diabetes mellitus, gastrointestinal bleeding, and severe renal failure are contraindications to corticosteroid use, though corticosteroids can be started after adequate control or reversal of infection, renal failure, and gastrointestinal bleeding. Prednisolone is preferred over prednisone; both are dosed 40 mg/day for a total of 4 weeks, with IV methylprednisolone 32 mg/day as the alternative for patients unable to take oral medication; there is no evidence supporting rapid vs slow tapering after the 4-week course. Corticosteroid response is assessed by Lille score at day 7 OR day 4 (day-4 shown as accurate as day-7); among non-responders (Lille >0.45) corticosteroids should be discontinued. ACG recommends IV N-acetylcysteine as an adjuvant to corticosteroids in severe AH (strong, moderate), while explicitly noting that other society guidelines have not adopted this recommendation. ACG recommends AGAINST pentoxifylline (strong, moderate) and AGAINST universal prophylactic antibiotics in hospitalized severe AH (strong, moderate); data on G-CSF and microbiome-based therapies are insufficient. Nutrition: target 35 kcal/kg/day with 1.2-1.5 g/kg/day protein; patients consuming <21 kcal/kg/day should receive nutritional support, preferably oral/enteral, oral nutritional supplements first, escalating to enteral nutrition if caloric targets remain unmet (strong, moderate). Thiamine, vitamin B12 and zinc deficiencies are common in AH and should be supplemented. For severe AH unresponsive to medical management with high risk of death, early liver transplantation for highly selected patients should be considered according to regional and institutional protocols (conditional recommendation, low level of evidence); LT selection must not be based solely on an arbitrary duration of sobriety, and should rest on detailed psychosocial evaluation by a social worker and addiction specialist, optionally supported by tools such as SIPAT, HRAR, MAPS, HPSS or SALT. For severe AH with 4 or more organ failures, non-responsive to corticosteroids and ineligible for early LT, palliative care engagement is appropriate.
Gallaher C … Parker R · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyprospective cohort · n=34,756 · Nov 1, 2026 · Liver International · IF 6.7
New evidencealcohol-associated liver diseaseepidemiologyMASLD
Clinical takeawayContinue to counsel patients on alcohol reduction as a key strategy to prevent liver disease, regardless of metabolic risk factors.
What it foundAlcohol intake remained associated with major adverse liver outcomes (HR 1.28 in 1992, HR 1.33 in 2012) despite rising metabolic risk factors.
ContextConfirms that alcohol remains a stable risk factor for liver outcomes, even as metabolic risk factors like obesity and diabetes have increased.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Katunin E … Åberg F · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyretrospective · n=388,933 · Oct 31, 2026 · Dig Liver Dis · IF 4.2
Clinical takeawayConsider incorporating ALK ≥120 U/L into FIB-4-based risk stratification for MASLD patients aged ≥35 years with BMI >27 kg/m² to refine triage and referral decisions for liver-related outcomes.
What it foundElevated ALK (≥120 U/L) increased 10-year MALO risk compared to normal ALK across FIB-4 strata: low (1.5% vs 1.1%), intermediate (2.8% vs 1.6%), and high (11.9% vs 4.5%), with adjusted HRs of 1.41, 2.58, and 9.57, respectively. FIB-4 and ALK were independently associated with MALO, with significant interaction (P < 0.001) and improved event reclassification.
ContextRefines current FIB-4-based risk stratification by adding cholestatic enzyme status, which independently predicts liver outcomes and improves risk reclassification in adults aged ≥35 years with MASLD or type 2 diabetes and BMI >27 kg/m².
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Shimoni O … Shlomai A · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Hepatologyprospective cohort · n=13,940 · Nov 1, 2026 · Liver International · IF 6.7
New evidenceviral hepatitisepidemiologyhealth servicescost-effectiveness
Clinical takeawayConsider dried blood spot (DBS) testing as a practical alternative to venepuncture for HCV screening in community and prison settings, particularly for high-risk populations. Prioritize strategies to improve treatment initiation post-testing, especially in community settings and among Aboriginal and/or Torres Strait Islander people.
What it found11% (1310/13940) of participants had current HCV infection, with higher treatment initiation in prison (64%) than community (37%) settings. Prevalence declined from 14% in 2019-2021 to 9% in 2022-2023. In community settings, Aboriginal and/or Torres Strait Islander people had lower odds of treatment initiation (aOR 0.69, 95% CI: 0.51-0.92). Treatment initiation in prison declined in 2022-2023 compared to 2019-2021 (aOR 0.64, 95% CI: 0.43-0.94).
ContextConfirms the utility of DBS testing for HCV screening in high-risk populations but highlights persistent gaps in treatment initiation, particularly in community settings and among Aboriginal and/or Torres Strait Islander people, and declining treatment initiation in prison settings.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA), "Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection" (Patients With Decompensated Cirrhosis section), 2023ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Diagnose active infection with HCV antibody testing with reflex HCV RNA PCR (Rating I, A); one-time opt-out anti-HCV testing is recommended for all adults ≥18 years and with each pregnancy (I, B), with annual testing for people who inject drugs, men with HIV who have unprotected sex with men, and MSM on PrEP (IIa, C). Treatment is recommended for all persons with acute or chronic HCV infection EXCEPT those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. Stage fibrosis noninvasively (FIB-4; biopsy not required). The simplified treatment algorithm applies only to treatment-naive adults and EXCLUDES prior HCV treatment, HBsAg positivity, current pregnancy, known or suspected HCC, prior liver transplantation, and any current or prior episode of decompensated cirrhosis; excluded patients are managed by the genotype/population-specific sections, not the simplified pathway. Treatment-naive WITHOUT cirrhosis (FIB-4 ≤3.25 and no other evidence of cirrhosis): glecaprevir 300 mg/pibrentasvir 120 mg once daily with food × 8 weeks, OR sofosbuvir 400 mg/velpatasvir 100 mg once daily × 12 weeks, both pangenotypic and equally recommended; pretreatment CBC, hepatic function panel, eGFR, quantitative HCV RNA, HIV, HBsAg, pregnancy test within 6 months, plus medication reconciliation for drug-drug interactions. Treatment-naive WITH compensated cirrhosis (Child-Pugh A): glecaprevir/pibrentasvir × 8 weeks for genotypes 1-6, OR sofosbuvir/velpatasvir × 12 weeks for genotypes 1, 2, 4, 5, and 6 only, in genotype 3 with compensated cirrhosis, baseline NS5A resistance testing is required before sofosbuvir/velpatasvir and the presence of Y93H changes the regimen; pretreatment labs within 3 months plus CTP score and liver ultrasound within 6 months. On treatment, no routine laboratory monitoring is required except counseling diabetic patients about hypoglycemia and monitoring INR in patients on warfarin. Decompensated cirrhosis (CTP class B or C, or any prior decompensation): refer to a practitioner with expertise, ideally at a liver transplant center; ALL protease-inhibitor-containing regimens (glecaprevir, grazoprevir, voxilaprevir) are contraindicated. Ribavirin-eligible, treatment-naive: sofosbuvir/velpatasvir + weight-based ribavirin × 12 weeks (all genotypes), or ledipasvir/sofosbuvir + ribavirin × 12 weeks for genotypes 1, 4, 5, 6; ribavirin-ineligible: sofosbuvir/velpatasvir (or ledipasvir/sofosbuvir for GT 1, 4, 5, 6) × 24 weeks without ribavirin; prior sofosbuvir-based or NS5A inhibitor-based treatment failure: sofosbuvir/velpatasvir + weight-based ribavirin × 24 weeks. In CTP class C, start ribavirin at 600 mg/day and increase as tolerated toward weight-based dosing. Cure is defined by quantitative HCV RNA undetectable ≥12 weeks after completing therapy (SVR12), checked with a hepatic function panel; patients without cirrhosis who achieve SVR need no further liver-related follow-up, while patients with cirrhosis continue HCC ultrasound surveillance every 6 months and variceal screening per AASLD guidelines after SVR. Repeat annual HCV RNA testing in anyone with ongoing exposure risk.
Stevens A … Grebely J · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyguideline · Oct 30, 2026 · Hepatology · IF 18.0
Clinical takeawayRefer to the new global ACLF definitions and grading system for patient stratification, organ dysfunction assessment, and critical care management, ensuring to consult the source for the specific criteria.
What it foundA global consensus established a unified, evidence-based framework for defining, diagnosing, grading, and managing acute-on-chronic liver failure (ACLF), though the specific criteria, categories, or cutoffs are detailed in the source.
ContextRefines and harmonizes existing regional definitions of ACLF, integrating diverse international perspectives to create a globally applicable standard.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
American Association for the Study of Liver Diseases (AASLD) … Society on Liver Disease in Africa (SOLDA) · Hepatology · IF 18.0 · PubMed ↗Permalink
Hepatologyguideline · Nov 1, 2026 · Liver International · IF 6.7
Clinical takeawayConsider integrating lifestyle interventions, GLP-1 receptor agonists (e.g., semaglutide, liraglutide), and bariatric surgery into the management of MASLD patients with obesity, and use noninvasive tools like Fibrosis-4 and vibration-controlled transient elastography for risk stratification. Note that resmetirom is FDA-approved for MASH with stage F2-F3 fibrosis, and therapy choice should be individualized to comorbidities, contraindications, and patient preference.
What it foundMASLD prevalence in Taiwanese adults is 30%-45%, reaching 60%-70% in individuals with obesity, with obesity accelerating hepatic and extrahepatic disease progression.
ContextThis position statement confirms the high prevalence of MASLD in Taiwan, particularly in obese individuals, and refines management strategies by emphasizing a multidisciplinary, precision-based approach. The recommendations align with AGA 2022 guidelines but highlight the need for individualized therapy based on patient-specific factors.
Reinforcessuggested applicable standard· American Gastroenterological Association, 'AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity' (Grunvald E et al., Gastroenterology 2022;163(5):1198-1225). DOI 10.1053/j.gastro.2022.08.045, PMID 36273831.ShowHide
PRIMARY, AGA 2022 (pharmacotherapy, the GI-society spine): Manage obesity as a chronic disease with lifestyle intervention as the foundation.…For metabolic/bariatric surgery, the 2022 ASMBS/IFSO indications recommend surgery at BMI ≥35 kg/m² regardless of comorbidity and consideration at BMI 30-34.9 kg/m² with metabolic disease (lower Asian-population thresholds: offer surgery at BMI >27.5, clinical obesity from >25), with multidisciplinary pre-operative evaluation.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
PRIMARY, AGA 2022 (pharmacotherapy, the GI-society spine): Manage obesity as a chronic disease with lifestyle intervention as the foundation. In adults with BMI ≥30 kg/m², OR BMI ≥27 kg/m² with a weight-related complication, who have an inadequate response to lifestyle intervention alone, the AGA STRONGLY recommends ADDING long-term pharmacotherapy to (not replacing) continued lifestyle intervention. Among agents the AGA suggests semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (all moderate-certainty evidence), and, as lower-certainty options, e.g., where cost is a barrier, phentermine and diethylpropion (low-certainty evidence); when prioritizing for greatest weight loss the panel favored semaglutide 2.4 mg. The AGA suggests AGAINST orlistat and made no recommendation on Gelesis100 (identified as a knowledge gap). Agent choice should be individualized to comorbidities, contraindications, patient preference, and cost/access. COMORBIDITY BRANCHES (attributed separately, NOT part of the AGA document): For obesity-associated MASH, AASLD Practice Guidance supports selecting patients with stage F2-F3 fibrosis by non-invasive tests (VCTE ~8-15 kPa, MRE 3.1-4.4 kPa, or ELF 9.2-10.5) rather than mandatory biopsy, and endorses resmetirom (thyroid hormone receptor-β agonist; FDA-approved March 2024) as the only currently approved pharmacotherapy for MASH (not indicated for MASH cirrhosis). For metabolic/bariatric surgery, the 2022 ASMBS/IFSO indications recommend surgery at BMI ≥35 kg/m² regardless of comorbidity and consideration at BMI 30-34.9 kg/m² with metabolic disease (lower Asian-population thresholds: offer surgery at BMI >27.5, clinical obesity from >25), with multidisciplinary pre-operative evaluation. Concurrently screen for and manage the GI/hepatology comorbidities of obesity (MASLD/MASH, GERD, cholelithiasis).
Clinical takeawayThe review calls for closer collaboration between hepatology and addiction medicine, and population-level alcohol reduction, to raise surveillance uptake in alcohol-related liver disease.
What it foundA substantial proportion of alcohol-related HCC is diagnosed at an advanced stage, often because underlying liver disease was not identified and surveillance was not implemented; alcohol use disorder, comorbidities and socioeconomic vulnerability complicate care.
ContextThis literature reports that alcohol-related hepatocellular carcinoma is frequently diagnosed at advanced stages due to missed early detection of underlying liver disease.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Mignot V … Costentin C · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyretrospective · n=164 · Nov 1, 2026 · Liver International · IF 6.7
New evidenceportal hypertensionhepatocellular carcinomabiomarker
Clinical takeawayConsider using the VITRO score (≤1.0) to rule out CSPH and (≥2.5) to rule in CSPH in patients with compensated advanced chronic liver disease (cACLD) and hepatocellular carcinoma (HCC), alongside Baveno VII criteria (LSM ≤15 kPa & PLT ≥150G/L) to reduce the grey zone to 16%. Note that PPVs were < 90%, reflecting the lower prevalence of CSPH in this population.
What it foundThe VITRO score (≤1.0) ruled out CSPH with 95% sensitivity and 87.9% NPV, and ruled in CSPH (≥2.5) with 89.8% specificity and 83.0% PPV in cACLD patients with HCC, compared to HVPG measurement.
ContextThis study confirms the utility of non-invasive tests (NITs) for CSPH in cACLD patients with HCC, refining the application of Baveno VII criteria and introducing the VITRO score as a complementary tool, though PPVs remain < 90%.
Refinessuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.ShowHide
…Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy.…Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.
Balcar L … Mandorfer M · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyrct · n=45 · Nov 1, 2026 · Liver International · IF 6.7
New evidenceviral hepatitisbiomarkerbasic sciencetranslational
Clinical takeawayConsider GST-HG131 for CHB patients on nucleos(t)ide therapy in clinical trials, as Phase IIa results show significant HBsAg reduction.
What it foundGST-HG131 reduced HBsAg by -0.89 log10 IU/mL after 12 weeks vs placebo (p < 0.001), with 76.5% achieving HBsAg < 100 IU/mL.
ContextCurrent CHB therapies rarely achieve functional cure due to persistent HBsAg and cccDNA. GST-HG131, a PAPD5/7 inhibitor, offers a novel mechanism targeting HBsAg production.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.
New evidenceviral hepatitisbasic sciencetranslationalbiomarker
Clinical takeawayThe review names bepirovirsen as the only agent with completed positive phase III results and notes combination regimens built on RNA-targeting backbones; it calls for long-term efficacy and safety data.
What it foundBepirovirsen, an RNA-targeting therapy, is the only agent completed in Phase III study showing efficacious results for functional cure in CHB.
ContextCurrent CHB therapies (NUCs and Peg-IFNα) rarely achieve functional cure despite viral suppression, leaving patients at risk for adverse liver outcomes. RNA-targeting therapies represent a novel approach.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.
New evidencevariceal bleedingportal hypertensionsystematic review
Clinical takeawayDescriptive pooled data without a meta-analysis, limited by small samples, missing data and heterogeneity, so they do not establish one endoscopic therapy over another.
What it foundAcross 44 mostly single-arm studies (458 patients), sclerosant injection appeared to rebleed less than banding for rectal varices (3.3% vs 33.3%), and TIPS with embolisation less than TIPS alone; pooled mortality was 25.0% after small-bowel, 42.9% after rectal and 66.6% after stomal variceal bleeding.
ContextDuodenal, rectal and stomal varices made up most cases.
Emergingsuggested applicable standard· AASLD, 'Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', Hepatology 2024 (PMID 37870298), the governing document for acute variceal hemorrhage. Baveno VII (J Hepatol 2022, PMID 35120736) is the consensus it operationalises. The prior citation, ACG 'Disorders of the Hepatic and Mesenteric Circulation' (2020), covers Budd-Chiari, portal vein thrombosis and mesenteric ischemia and does NOT address variceal bleeding, a mis-anchor, not a stale edition.ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
For acute variceal hemorrhage in cirrhosis, resuscitate conservatively with a restrictive RBC transfusion strategy targeting hemoglobin 7-8 g/dL, start a vasoactive agent as soon as bleeding is suspected and before endoscopy (terlipressin, somatostatin, or octreotide; octreotide is the agent available for this indication in US practice) and continue it 2-5 days, and give empiric IV ceftriaxone 1 g every 24 hours in patients with advanced cirrhosis. Perform upper endoscopy within 12 hours of presentation once resuscitated, or as soon as safely possible if the patient is unstable, with band ligation for esophageal varices and for GOV1 (which is treated as an esophageal varix); cardiofundal varices (GOV2 and IGV1) are treated with cyanoacrylate injection, with EUS-guided coil placement with or without cyanoacrylate increasingly used as first-line where expertise exists, and TIPS or BRTO as alternatives or salvage. PPIs started empirically should be stopped immediately after endoscopy unless there is a separate strict indication. Evaluate every patient at presentation for pre-emptive (early) TIPS with a PTFE-covered stent, placed within 72 hours and ideally within 24 hours, in high-risk patients defined as Child-Pugh class C with score under 14 (that is, 10-13) or Child-Pugh class B with score above 7 who have active bleeding at initial endoscopy despite vasoactive drugs; the decision is individualized and multidisciplinary, weighing age, frailty, comorbidity, heart failure, HCC, portal vein thrombosis, and transplant candidacy. For uncontrolled bleeding, a self-expanding covered esophageal metal stent is as effective as balloon tamponade and is the safer option; both are a bridge to definitive therapy (PTFE-covered TIPS) and neither is definitive therapy. Balloon tamponade must NOT be left in place for more than 24 hours, 24 hours is the ceiling, not a range: Baveno VI states it "should only be used in refractory oesophageal bleeding, as a temporary bridge (for a maximum of 24 h) with intensive care monitoring and considering intubation, until definitive treatment can be instituted", because severe esophageal injury/necrosis, perforation and aspiration rise sharply beyond that point. The 72-hour figure in this standard belongs to the pre-emptive TIPS window and must not be read as a permissible tamponade duration. Secondary prophylaxis is mandatory in all survivors and is combination therapy: a nonselective beta-blocker, either a traditional NSBB (propranolol or nadolol) or carvedilol, which Baveno VII endorses as an equivalent rather than clearly superior option in this specific indication, plus serial EVL every 2 to 8 weeks until variceal eradication, with surveillance endoscopy thereafter. TIPS is the treatment of choice for patients who rebleed despite NSBB plus EVL.
Clinical takeawayConsider using PSC-DM in non-specialist settings for initial diagnostic assessment to improve diagnostic accuracy and facilitate timely referral to expert centers.
What it foundPSC-DM, a model using six clinical variables (younger age at presentation, presence of IBD, absence of prior hepato-pancreato-biliary surgery, autoimmune comorbidities, family history of autoimmune diseases, and absence of pancreatic abnormalities), achieved an AUROC of 0.95 (95% CI 0.91-0.98) for distinguishing PSC from SSC.
ContextConfirms the utility of clinical variables in differentiating PSC from SSC in adults with established diagnoses, addressing a longstanding diagnostic challenge in hepatology.
Emergingsuggested applicable standard· AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guidelineShowHide
Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease. No disease-modifying therapy is proven to alter transplant-free survival, but moderate-dose UDCA (13-23 mg/kg/day) may now be considered and continued in patients not enrolled in or eligible for a clinical trial if it produces a meaningful improvement in alkaline phosphatase (GGT in children) and/or symptoms by 12 months, discontinuing if no response; high-dose UDCA remains contraindicated. Perform annual abdominal MRI/MRCP with or without serum CA19-9 for cholangiocarcinoma/gallbladder-cancer surveillance in adults with large-duct PSC (not recommended under age 18 or in small-duct PSC). Manage gallbladder polyps by size, cholecystectomy for polyps >8 mm, ultrasound surveillance every 6 months for polyps ≤8 mm, rather than referring every polyp. For colorectal surveillance, begin surveillance colonoscopy at the time of PSC-IBD diagnosis (or at age 15 for childhood-onset disease) and repeat at 1-2 year intervals; in PSC without IBD, perform a diagnostic colonoscopy at PSC diagnosis and repeat every 5 years if IBD is not found. Evaluate dominant strictures with brush cytology plus FISH (± cholangioscopy) before/at balloon dilation, repeating ERCP with sampling in 3 months if cytology is suspicious regardless of FISH result. Treat recurrent cholangitis and cholestatic pruritus, maintain bone health, and refer for transplant evaluation for decompensation, intractable pruritus, recurrent bacterial cholangitis, or early-stage CCA per Mayo protocol.
Scaravaglio M … Culver EL · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyprospective cohort · n=3,568 · Oct 25, 2026 · J Gastro Hep · IF 3.5
Clinical takeawayLean MASLD carried higher all-cause mortality in the first 10 years (HR 1.68) but not afterwards, and no association with cardiovascular mortality, in an observational NHANES III analysis; it does not define a separate follow-up schedule.
What it foundLean MASLD increased all-cause mortality within 0-10 years (HR 1.68, 95% CI 1.29-2.20) but not thereafter (HR 1.04, 95% CI 0.87-1.25), with no significant association with cardiovascular mortality.
ContextHighlights a time-dependent mortality risk in lean MASLD, particularly within the first decade post-diagnosis, which aligns with existing concerns about MASLD prognosis.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
…Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking.…A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Clinical takeawayConsider using ESC Cardio-Oncology classification or CARDIOSOR score to stratify cardiovascular risk in patients with uHCC before initiating atezolizumab/bevacizumab therapy. For high-risk patients, weigh bevacizumab-free alternatives as a comparator.
What it foundPatients classified as very high-risk by ESC Cardio-Oncology classification (specific thresholds not provided in abstract) or high-risk by CARDIOSOR score (specific thresholds not provided in abstract) had significantly increased risk of tMACE (3.7%) and eMACE (5.6%).
ContextThis study provides evidence for cardiovascular risk stratification in uHCC patients on atezolizumab/bevacizumab, addressing a gap in cirrhosis-specific risk assessment.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Stefanini B … ARTE Study Group · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyprospective cohort · n=114 · Nov 1, 2026 · Liver International · IF 6.7
New evidencebasic sciencetranslationalbiomarkerepidemiology
Clinical takeawayConsider monitoring LSVR in PSVD patients to assess prognosis and guide management decisions.
What it foundLiver-to-spleen volume ratio (LSVR) predicts liver-related events in PSVD with an optimal cut-off of 1.33 (16.2% events over 6.7 years).
ContextThis study introduces LSVR as a novel prognostic marker in PSVD, refining current practice which lacks established predictors of disease progression.
Measured against the standard of care· AASLD/EASL/APASL/ALEH multisociety consensus 2026 (diagnosis) / AASLD 2021 vascular liver disorders guidance (management)ShowHide
…PSVD/NCPF can coexist with another chronic liver disease as long as the biopsy shows no cirrhosis.…Minor histology is any of: regenerative changes without NRH, abnormal distribution of vascular structures, or portal venule stenosis in 25-49% of portal tracts.…A total of 2 or less means the diagnosis cannot be made, 3-4 is possible PSVD/NCPF (follow up and/or refer to an expert center), and 5 or more is confirmed.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Diagnosis now follows the 2026 multisociety consensus (AASLD, EASL, APASL and ALEH, with the pathology and pediatric societies ESP, Hans Popper, SGIHPBPs, NASPGHAN and ESPGHAN). PSVD and NCPF are interchangeable names for one clinicopathological diagnosis. A liver biopsy is mandatory, and it must exclude cirrhosis. A specimen of at least 15 mm with at least one fragment of 10 mm or more is enough to do that. The listed alternative conditions must also be excluded. Signs of portal hypertension are no longer required for the diagnosis. PSVD/NCPF can coexist with another chronic liver disease as long as the biopsy shows no cirrhosis. Major histology is any of: NRH, muscularized portal venules, or portal venule stenosis in at least 50% of portal tracts. Minor histology is any of: regenerative changes without NRH, abnormal distribution of vascular structures, or portal venule stenosis in 25-49% of portal tracts. All three minor criteria together count as one major criterion. Specific signs of portal hypertension are variceal bleeding, medium or large esophageal varices, gastric varices, spontaneous portosystemic shunts, spleen stiffness above 40 kPa without an MPN, and HVPG or porto-caval gradient of 10 mmHg or more. Non-specific signs are clinical ascites, small varices, platelets below 150 G/L and splenomegaly. Scoring takes only the highest item in each domain. Portal hypertension scores 0 if absent, 2 if only non-specific signs, 3 if any specific sign. Histology scores 0 if normal, 2 for up to two minor criteria, 5 for any major criterion or all three minor. An associated condition adds 1. A concomitant cause of cirrhosis subtracts 1; metabolic syndrome without biopsy-proven MASLD does not count. A total of 2 or less means the diagnosis cannot be made, 3-4 is possible PSVD/NCPF (follow up and/or refer to an expert center), and 5 or more is confirmed. Low liver stiffness with high spleen stiffness, MRI periportal hyperintensity, or a nodular surface with a normal or enlarged segment IV add suspicion but no points. Three former exclusions were dropped. An intrahepatic portal cavernoma no longer excludes the diagnosis. SOS diagnosed more than 6 months earlier after stem cell transplant no longer excludes it. In endemic areas without hepatosplenic schistosomiasis, positive schistosomal serology or a few eggs on biopsy no longer exclude it. The consensus does not cover management, so management is unchanged from AASLD 2021. Look for associated conditions and causes: drugs, MPN, thrombophilia, PNH, autoimmune disease, CVID, HIV. Manage portal hypertension complications as in cirrhosis: NSBB (carvedilol preferred) or EVL for variceal prophylaxis, and TIPS for refractory or recurrent bleeding. Stop offending drugs and treat the specific cause. Decide on anticoagulation for coexisting PVT case by case, weighing thrombus acuity, bleeding risk and cause. Reserve liver transplant for refractory complications. HCC surveillance is not routine without cirrhosis.
New evidencesystematic reviewmeta-analysispediatricparenteral nutrition
Clinical takeawayNo clinical action yet: this meta-analysis found no difference in outcomes between low-dose (1 g/kg/day) and standard-dose (2-3 g/kg/day) SO-ILE in neonates, so current dosing practices remain unchanged.
What it foundLow-dose (1 g/kg/day) and standard-dose (2-3 g/kg/day) SO-ILE showed no significant differences in PNAC (53.4% vs. 48.5%), mortality (5.7% vs. 6.2%), or growth outcomes in neonates.
ContextConfirms current practice: prior evidence suggested lipid restriction might reduce PNAC risk, but this meta-analysis found no benefit to low-dose SO-ILE in neonates.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Lima NA … Butler MW · JPEN. Journal of Parenteral and Enteral Nutrition · IF 3.2 · PubMed ↗Permalink
Hepatologymeta analysis · n=2,142 · Nov 1, 2026 · Liver International · IF 6.7
New evidenceMASLDmeta-analysisbiomarkerepidemiology
Clinical takeawayNo clinical action yet: this meta-analysis identifies an association between IPFD and LFC in T2DM at the study level, but individual-level analyses are needed to clarify clinical implications.
What it foundIndividuals with T2DM had significantly higher liver fat content (LFC) than non-diabetic controls (SMD 0.89, 95% CI 0.60-1.18), with larger excess in studies with mean intrapancreatic fat deposition (IPFD) ≥ 10% (SMD 1.20 vs. 0.62; p = 0.04).
ContextThis meta-analysis confirms that T2DM is associated with higher LFC and suggests a potential link with IPFD, refining prior evidence on metabolic fat distribution in T2DM.
Emergingsuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.
New evidencebasic sciencebiomarkerpediatricepidemiology
Clinical takeawayNo clinical action yet: PRSs may improve risk stratification but lack diagnostic accuracy (AUROC <60%) for advanced fibrosis in MASLD.
What it foundSchwantes-An PRS in adults (OR 1.29, 95% CI 1.17-1.42) and Chen PRS in children (OR 1.46, 95% CI 1.17-1.82) were associated with higher risk of advanced fibrosis in MASLD.
ContextRefines understanding of genetic risk in MASLD, suggesting distinct PRSs may aid risk stratification in adults vs. children, but does not yet challenge current diagnostic practices.
Emergingsuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.ShowHide
Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.
Gawrieh S … Chalasani N · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyrct · n=70 · Oct 26, 2026 · Hepatology · IF 18.0
Clinical takeawayNo clinical action yet: phase 1b study in MASH patients evaluating dosing regimens and safety. Treatment-emergent adverse events led to drug interruption/discontinuation in 12.9% of patients.
What it foundIntermittent miricorilant 100 mg twice weekly reduced liver fat content by 28.2% at week 12 and improved liver enzymes (ALT -3.8 U/L, AST -6.0 U/L) compared to baseline in patients with presumed MASH.
ContextThis is early-phase evidence for a novel glucocorticoid receptor modulator in MASH, exploring dosing strategies to optimize efficacy and safety.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
…Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Clinical takeawayNo clinical action yet: a mechanistic finding in humans with preclinical validation in mice and cell culture.
What it foundPhosphatidylserine (PS) externalization had higher discriminatory performance for 6-month HCC recurrence/progression than RDW-CV (AUC 0.804 vs 0.642).
ContextChallenges the role of RDW as a biomarker in HCC by proposing PS externalization as a superior marker for early recurrence/progression.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Tan M … Huang H · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Hepatologyprospective cohort · n=79 · Nov 1, 2026 · Liver International · IF 6.7
Clinical takeawayNo clinical action yet: HGF is a prognostic biomarker in non-APAP-DILI-ALI/ALF, but its clinical utility requires validation in a prospective cohort.
What it foundHGF levels were markedly elevated in non-APAP-DILI-ALI/ALF patients (5070 ± 4001 pg/mL vs. 276 ± 581 pg/mL in healthy donors) and highest in those who died or underwent transplantation (6421 ± 4359 pg/mL vs. 4102 ± 3456 pg/mL; p = 0.009).
ContextChallenges current reliance on MELD score by suggesting HGF may improve risk stratification in non-APAP-DILI-ALF, particularly in the ALF subgroup (AUC 0.811 vs. 0.643 for MELD).
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), "AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury" (Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V), Hepatology, 2023 (Guidance Statement 13)ShowHide
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standardShowHide
Initiate the DILI evaluation only for clinically significant liver injury, serum AST or ALT > 5× ULN, or ALP > 2× ULN (or the pretreatment baseline if that value is abnormal) on two separate occasions; total serum bilirubin > 2.5 mg/dL with an elevated AST, ALT or ALP; or INR > 1.5 with an elevated AST, ALT or ALP, not for any minor liver-test abnormality (GS 13). In a patient with new liver test abnormalities after drug, herbal or dietary supplement (HDS) exposure, take a detailed medication and HDS history including intravenous agents such as monoclonal antibodies; most hepatotoxic drugs cause injury within the first 6 months, though some agents have longer latency and hypersensitivity reactions may appear within 24-72 hours (GS 14). Treat DILI as a diagnosis of exclusion: test for hepatitis A IgM, HBsAg, anti-HBc IgM and HCV RNA, obtain autoantibodies (ANA, anti-smooth muscle) and serum immunoglobulins, add antimitochondrial antibody in cholestatic presentations, test anti-HEV IgM in selected cases, and image the biliary tree, usually with abdominal ultrasound (GS 16). Categorize the case by R value at presentation, R = (ALT/ULN)/(ALP/ULN) (GS 15). Liver biopsy is NOT required for diagnosis but may help in severe or protracted cases, when there is diagnostic uncertainty, or when biochemistries/symptoms fail to improve after dechallenge (GS 19-20). For causality, note that the guidance does not endorse a single instrument: it describes three commonly used methods each with strengths and limitations (GS 24), observes that DILIN semiquantitative expert opinion is frequently used in practice and research but requires specialized expertise that limits generalizability (GS 26), and that updated RUCAM has better instructions but retains age, alcohol and pregnancy as risk factors of unclear value (GS 27). Management: discontinuation of the suspect drug plus supportive care, antiemetics, antipruritics, hydration, is the mainstay (GS 39). A short course of intravenous N-acetylcysteine may benefit hospitalized ADULT patients with DILI-related acute liver failure, but NAC is NOT recommended for children (GS 40); in acetaminophen overdose with established liver injury, continue NAC infusion at 6.25 mg/kg/h until ALT is falling and INR < 2. Corticosteroids for 1-3 months may benefit selected patients, severe hypersensitivity features, DRESS, immune checkpoint inhibitor injury with ALT > 5× ULN, or autoimmune-like features on biopsy, but optimal dose and duration are unknown for lack of controlled trials; typical dosing is prednisone 40-60 mg/day, or methylprednisolone-equivalent 1 mg/kg/day for checkpoint inhibitor cases (GS 41). Ursodeoxycholic acid is not established therapy but is presumably safe, and may be used at 10-15 mg/kg/day in divided doses for severe pruritus (GS 42). Because spontaneous survival in idiosyncratic DILI-related acute liver failure is only about 25%, transfer such patients EARLY to a liver transplant center (GS 36); roughly 10% of registry patients suffer ALF, transplant or death within 6 months (GS 35), with higher bilirubin and INR, lower albumin, severe necrosis or fibrosis on biopsy, comorbidity burden, and pre-existing liver disease marking increased risk (GS 38). Rechallenge with the suspect drug should generally be avoided UNLESS the anticipated benefit is high for a severe or life-threatening condition, e.g. isoniazid rechallenge causes recurrent injury in only 10% but should be attempted only in active, drug-resistant TB (GS 44). Follow liver tests to resolution: DILI persisting beyond 6-12 months (chronic DILI) occurs in 10%-20% of patients (GS 37).
New evidencecirrhosisportal hypertensionhepatic encephalopathyacute liver failure
Clinical takeawayNo clinical action yet: this retrospective observational study suggests extending albumin treatment beyond 24 h does not improve outcomes, but prospective trials are needed to confirm this.
What it foundIn a retrospective observational study of HRS-AKI patients with cirrhosis and ascites, extending albumin treatment beyond 24 h (vs. <24 h) did not improve terlipressin response (40.7% complete response) or HD-/LT-free survival.
ContextChallenges the assumption that longer albumin treatment before terlipressin improves outcomes in HRS-AKI, supporting individualized volume expansion strategies in patients with cirrhosis and ascites.
Reinforcessuggested applicable standard· International Club of Ascites (ICA) & Acute Disease Quality Initiative (ADQI), "Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting," Journal of Hepatology, 2024ShowHide
…TREAT: immediately on diagnosis start a vasoconstrictor plus 20-25% albumin (strong recommendation, grade A). Terlipressin is first-line, continuous IV infusion 2-12 mg/day, titrated up by ≥2 mg/day every 24h to a maximum 12 mg/day if serum creatinine has not fallen ≥25%; or IV bolus 1-2 mg every 6h, escalated from 1 mg to 2 mg every 6h on that same ≥25% serum-creatinine response threshold, with the 12 mg/day maximum applying only to continuous infusion and not to bolus dosing.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Per the 2024 ADQI-ICA joint consensus (which updates the 2015 ICA-AKI criteria referenced in AASLD 2021), in a patient with cirrhosis and ascites: DIAGNOSE HRS-AKI when all of (a) cirrhosis with ascites; (b) AKI by KDIGO/ICA criteria, serum creatinine rise ≥0.3 mg/dL (26.5 µmol/L) within 48h or ≥50% from a baseline known or presumed within the prior 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6h (strong recommendation, grade A); (c) absence of improvement in serum creatinine and/or urine output within 24h following adequate volume resuscitation WHEN CLINICALLY INDICATED, the consensus recommends AGAINST systematic 48h albumin administration as a diagnostic requisite (strong recommendation, grade D), and only where volume status is equivocal is a single fluid challenge (250-500 mL crystalloid, or 1-1.5 g/kg of 20-25% albumin) assessed within 24h; and (d) absence of strong evidence for an alternative primary cause of AKI (e.g., septic shock requiring vasopressors, acute glomerular injury, obstruction, or nephrotoxin-induced AKI) (not graded). HRS-AKI is a phenotype specific to advanced cirrhosis and ascites: coexisting CKD, tubular injury or proteinuria do NOT exclude it, and it may coexist with, or be superimposed on, other AKI etiologies rather than requiring pure exclusion. TREAT: immediately on diagnosis start a vasoconstrictor plus 20-25% albumin (strong recommendation, grade A). Terlipressin is first-line, continuous IV infusion 2-12 mg/day, titrated up by ≥2 mg/day every 24h to a maximum 12 mg/day if serum creatinine has not fallen ≥25%; or IV bolus 1-2 mg every 6h, escalated from 1 mg to 2 mg every 6h on that same ≥25% serum-creatinine response threshold, with the 12 mg/day maximum applying only to continuous infusion and not to bolus dosing. If terlipressin is unavailable or contraindicated, norepinephrine (continuous infusion 0.5-3 mg/h, up-titrated 0.5 mg/h every 4h to raise MAP ≥10 mmHg; requires ICU care and a central line) may be more appropriate. Midodrine 7.5-15 mg PO every 8h plus octreotide 100-200 µg SC every 8h with albumin is third-line, considered only if terlipressin is contraindicated AND transfer to ICU for norepinephrine is not possible. Give 20-25% albumin 20-40 g/day with any vasoconstrictor, adjusted daily to volume status and withheld for fluid overload/pulmonary edema. Discontinue vasoconstrictors when serum creatinine returns to within 0.3 mg/dL of baseline, for a severe adverse reaction, if kidney function does not improve after 48h at maximum tolerated dose, if RRT is indicated, or at a maximum of 14 days of therapy (strong recommendation, grade B). Initiation of RRT should be individualized to clinical context and anticipated or observed life-threatening AKI-related complications (best-practice statement) rather than framed strictly as a transplant-bridge measure. Recommend expedited evaluation for liver transplantation following an episode of AKI (best-practice statement); LT in selected patients is the definitive treatment for HRS-AKI regardless of vasoconstrictor response (strong recommendation, grade A), with vasoconstrictors serving as a bridge to transplantation or renal recovery rather than a cure.
Schleicher EM … German cirrhosis study group · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatologyreview · Nov 1, 2026 · Liver International · IF 6.7
Clinical takeawayNo clinical action yet: a mechanistic review of HPC-DR interactions in liver disease progression.
What it foundThe ductular reaction (DR) driven by hepatic progenitor cells (HPCs) facilitates parenchymal restoration in early liver injury but fuels progressive fibrogenesis in chronic disease.
ContextThis review refines understanding of DR's dual role in liver repair and fibrosis, integrating recent mechanistic insights from preclinical models.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
Decision at stakethe role of hepatic progenitor cells and ductular reaction in MASLD progression
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Clinical takeawayNo clinical action yet: this is a review proposing a framework for future trial design and care in MASH cirrhosis, not a study of a specific intervention.
What it foundMost agents evaluated in compensated MASH cirrhosis did not meet their prespecified primary endpoints, and structural change may require longer exposure.
ContextChallenges current trial design by highlighting the need for stage-specific approaches and longer treatment durations in MASH cirrhosis, rather than treating it as an extension of precirrhotic MASH.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
Decision at stakethe management of MASH cirrhosis
…Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities.…In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
Clinical takeawayNo clinical action yet: exploratory findings in humans linking small-intestinal motility to microbiota and metabolic tissue expression, requiring further investigation for causality and clinical relevance.
What it foundSmall-intestinal motility in MASLD patients correlated with fecal microbiota (Verrucomicrobia and Bacteroidetes phyla, 41 species), liver mRNA expression of CBS (FDR-P < 0.001), and adipose tissue mRNA expression of SCARB1 and SCD1 (FDR-P < 0.05).
ContextOpens a question on the interplay between small-intestinal motility, gut microbiota, and metabolic tissue expression in MASLD, a relationship not previously explored in humans.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Houttu V … Jonge CS · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink